uniQure (NASDAQ:QURE) Trading Down 4.4% – Here’s Why

uniQure N.V. (NASDAQ:QURE) traded down 4.4% during mid-day trading on Thursday . The stock traded as low as $44.17 and last traded at $44.1810. 452,545 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 2,365,216 shares. The stock had previously closed at $46.23.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research note on Saturday. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Wednesday, July 29th. The Goldman Sachs Group lifted their target price on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. Barclays cut their price target on uniQure from $65.00 to $60.00 and set an “overweight” rating on the stock in a research note on Thursday, July 30th. Finally, William Blair initiated coverage on uniQure in a research report on Wednesday. They issued an “outperform” rating on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $65.00.

uniQure Stock Down 0.8%

The firm’s 50 day moving average is $44.30 and its two-hundred day moving average is $30.34. The firm has a market cap of $3.09 billion, a P/E ratio of -11.10 and a beta of 0.94. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period in the previous year, the company posted ($0.69) EPS. As a group, research analysts anticipate that uniQure N.V. will post -3.82 EPS for the current fiscal year.

Insider Activity

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director directly owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the completion of the sale, the insider owned 148,235 shares of the company’s stock, valued at $6,881,068.70. This trade represents a 16.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 385,584 shares of company stock worth $16,737,722 in the last 90 days. Corporate insiders own 4.65% of the company’s stock.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new stake in uniQure during the 2nd quarter worth approximately $15,254. IFP Advisors Inc acquired a new position in shares of uniQure in the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure in the fourth quarter valued at approximately $48,000. CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure during the third quarter worth $50,000. Finally, Ensign Peak Advisors Inc raised its holdings in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 650 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.